[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:lung-non-small-cell-squamous-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":79,"states":80},"Lung Non-Small Cell Squamous Carcinoma",11,10,[8,16,23,29,35,41,47,54,61,67,73],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06692738","A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)",[12],"Phase 3","RECRUITING","2026-08-26T02:19:06.150683Z","2026-07-19T19:36:05.037066Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06568939","A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",[20],"Phase 2","2026-08-26T02:15:09.079045Z","2026-07-05T05:32:16.763326Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07217301","A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer",[12],"2026-08-26T02:15:53.461103Z","2026-07-05T05:32:16.669823Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07680764","A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[20],"2026-08-26T02:18:11.042248Z","2026-07-05T03:45:20.444006Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06422143","Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]",[12],"2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.543226Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05613413","A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)",[20],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:28.335818Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT07164313","A Study of ZW251 in Participants With Advanced Solid Tumors",[51],"Phase 1","2026-08-26T02:18:20.384845Z","2026-05-05T02:43:29.384442Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT07602842","A Study of IDP-001 in Advanced or Metastatic Solid Tumors",[58],"Phase 1\u002FPhase 2","2026-08-26T02:17:12.307088Z","2026-05-29T15:36:40.222864Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07169734","A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors",[58],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:29.532182Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT04977453","GI-101\u002FGI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors",[58],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:27.611815Z",{"nct_id":74,"title":75,"phases":76,"status":77,"updated_at":45,"content_modified":78},"NCT07680790","Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)",[12],"NOT_YET_RECRUITING","2026-07-05T03:45:20.442452Z",[],[81,85,89,93,96,100,104,108,111,114,117,120,123,126,129,133,136,139,142,145,148],{"state":82,"count":83,"slug":84},"Texas",9,"texas",{"state":86,"count":87,"slug":88},"California",8,"california",{"state":90,"count":91,"slug":92},"New Jersey",7,"new-jersey",{"state":94,"count":91,"slug":95},"New York","new-york",{"state":97,"count":98,"slug":99},"Illinois",6,"illinois",{"state":101,"count":102,"slug":103},"Florida",5,"florida",{"state":105,"count":106,"slug":107},"Arkansas",4,"arkansas",{"state":109,"count":106,"slug":110},"Georgia","georgia",{"state":112,"count":106,"slug":113},"Kentucky","kentucky",{"state":115,"count":106,"slug":116},"Nebraska","nebraska",{"state":118,"count":106,"slug":119},"North Carolina","north-carolina",{"state":121,"count":106,"slug":122},"Pennsylvania","pennsylvania",{"state":124,"count":106,"slug":125},"Tennessee","tennessee",{"state":127,"count":106,"slug":128},"Virginia","virginia",{"state":130,"count":131,"slug":132},"Arizona",3,"arizona",{"state":134,"count":131,"slug":135},"Connecticut","connecticut",{"state":137,"count":131,"slug":138},"Maryland","maryland",{"state":140,"count":131,"slug":141},"Michigan","michigan",{"state":143,"count":131,"slug":144},"Minnesota","minnesota",{"state":146,"count":131,"slug":147},"Ohio","ohio",{"state":149,"count":131,"slug":150},"Washington","washington"]